Triderm 0.5 mg/10 mg/1 mg/g unguent Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

triderm 0.5 mg/10 mg/1 mg/g unguent

organon central east gmbh - betamethasonum + denumirea comuna internationala + gentamicinum - unguent - 0.5 mg/10 mg/1 mg/g

Advagraf 0,5 mg capsule cu eliberare prelungită Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

advagraf 0,5 mg capsule cu eliberare prelungită

astellas pharma europe b.v. - tacrolimus - capsule cu eliberare prelungită - 0,5 mg

Advagraf 1 mg capsule cu eliberare prelungită Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

advagraf 1 mg capsule cu eliberare prelungită

astellas pharma europe b.v. - tacrolimus - capsule cu eliberare prelungită - 1 mg

Advagraf 5 mg capsule cu eliberare prelungită Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

advagraf 5 mg capsule cu eliberare prelungită

astellas pharma europe b.v. - tacrolimus - capsule cu eliberare prelungită - 5 mg

Canespor crema 10 mg/g Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

canespor crema 10 mg/g

bayer s.r.l. - bifonazolum - crema - 10 mg/g

Azarga Uniunea Europeană - română - EMA (European Medicines Agency)

azarga

novartis europharm limited - brinzolamida, maleat de timolol - glaucoma, open-angle; ocular hypertension - oftalmologice - scăderea presiunii intraoculare (pio) la pacienții adulți cu glaucom cu unghi deschis sau hipertensiune oculară pentru care monoterapia asigură o reducere insuficientă a pio.

Azopt Uniunea Europeană - română - EMA (European Medicines Agency)

azopt

novartis europharm limited - brinzolamidă - glaucoma, open-angle; ocular hypertension - oftalmologice - azopt este indicat pentru reducerea presiunii intraoculare crescute în:hipertensiune oculară;unghi deschis glaucomaas monoterapie la pacienții adulți care nu raspund la beta-blocante sau la pacienții adulți la care beta-blocantele sunt contraindicate, sau ca terapie adjuvantă la beta-blocante sau analogi de prostaglandine.

Prezista Uniunea Europeană - română - EMA (European Medicines Agency)

prezista

janssen-cilag international nv - darunavir - infecții cu hiv - antivirale pentru uz sistemic - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

CANESPOR ONICHOSET 10mg+400mg//g România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

canespor onichoset 10mg+400mg//g

bayer s.r.l. - combinatii - unguent - 10mg+400mg/g - antifungice pentru uz topic derivati de imidazol si triazol

TRIDERM 0,5 mg+10 mg+1 mg/gram România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

triderm 0,5 mg+10 mg+1 mg/gram

schering plough labo nv - belgia - combinatii - crema - 0,5mg+10mg+1mg/gram - corticosteroizi in combinatii cu antibiotice corticosteroizi cu potenta mare in comb. cu antibiotice